Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low an...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Koefoed, Klaus, Steinaa, Lucilla, Søderberg, Josefine Nielsen, Kjær, Ida, Jacobsen, Helle Jane, Meijer, Per-Johan, Haurum, John Sørensen, Jensen, Allan, Kragh, Michael, Andersen, Peter Sejer, Pedersen, Mikkel Wandahl
Format: Artigo
Langue:Inglês
Publié: Landes Bioscience 2011
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242845/
https://ncbi.nlm.nih.gov/pubmed/22123060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.3.6.17955
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires